Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed)

Funding Opportunity PA-19-066 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding

Related Links:

The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
The Trump administration chose 5 companies as the most likely to produce a vaccine. The tally of new cases is rising in the U.S., partly because of expanded testing. Italy ends travel restrictions.
Source: NYT Health - Category: Consumer Health News Tags: Coronavirus (2019-nCoV) Source Type: news
A senior U.S. Army vaccine researcher said on Tuesday it was reasonable to expect that some sort of coronavirus vaccine could be available to part of the U.S. population by the end of the year.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The Trump administration has selected five companies, including Moderna Inc, AstraZeneca Plc and Pfizer Inc, as the most likely candidates to produce a vaccine for the novel coronavirus, the New York Times reported on Wednesday, citing senior officials.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Turkey’s health minister says Turkey and Russia have agreed to cooperate in the development of a coronavirus vaccine and plan to carry out joint clinical trials
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Brazil's health regulator Anvisa has approved human clinical trials for a potential coronavirus vaccine developed by scientists at Oxford University and supported by AstraZeneca Plc, it said on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Conclusion Medical device specialists want to help, but responding to pandemic shortages can be complicated. These takeaways come from our experience with building PPE, but they apply to any collaborative rapid response project. Use these tips as a framework to get you and your team on the path to meaningful progress.
Source: MDDI - Category: Medical Devices Authors: Tags: Design Source Type: news
The GAVI vaccines alliance is to launch an Advance Market Commitment (AMC) for future COVID-19 vaccines which it says will help secure access to the new shots for poorer countries.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The nation that produces the first safe and effective vaccine will gain not only bragging rights but also a fast track to put its people back to work, a powerful public health tool to protect its citizens and a precious resource to reward allies.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
More News: Clinical Trials | Contracts | Funding | Grants | Infectious Diseases | Research | Study | Vaccines